Hao You1, Yao Wu1, Kai Chang1, Xiao Shi1, Xin-Da Chen1, Wei Yan2, Rui Li2. 1. KangDa College of Nanjing Medical University, Nanjing, China. 2. Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Abstract
AIMS: The purpose of this study was to explore the clinical significance of telomerase reverse transcriptase (TERT) promoter mutations in gliomas. METHODS AND RESULTS: We used DNA sequencing data to analyze 887 gliomas for TERT promoter mutations based on histological and genetic backgrounds. TERT promoter mutations were detected in 39.6% of low-grade gliomas, 40.3% of anaplastic gliomas, 44.7% of primary glioblastomas, 29.4% of secondary glioblastomas, and in 29.7% of Proneural, 38.6% of Neural, 41.8% of Classical, and 41.6% of Mesenchymal subtypes. Frequency of C250T mutation in recurrent gliomas was approximately half that in newly diagnosed gliomas. TERT exhibited improved prognosis when co-occurred with isocitrate dehydrogenase 1 (IDH1) and 1p19q alteration, but experienced inverse survival in the Mesenchymal subtype or tumor protein p53 (TP53) and epidermal growth factor receptor (EGFR) alteration. Furthermore, the five subtypes were classified based on the prognostic impact of the TERT mutation with different genetic backgrounds of glioma. CONCLUSION: We describe the TERT promoter mutation spectrum according to the histological, genetic, and molecular subtypes of glioma, which may aid in glioma subtype classification and have clinical implications.
AIMS: The purpose of this study was to explore the clinical significance of telomerase reverse transcriptase (TERT) promoter mutations in gliomas. METHODS AND RESULTS: We used DNA sequencing data to analyze 887 gliomas for TERT promoter mutations based on histological and genetic backgrounds. TERT promoter mutations were detected in 39.6% of low-grade gliomas, 40.3% of anaplastic gliomas, 44.7% of primary glioblastomas, 29.4% of secondary glioblastomas, and in 29.7% of Proneural, 38.6% of Neural, 41.8% of Classical, and 41.6% of Mesenchymal subtypes. Frequency of C250T mutation in recurrent gliomas was approximately half that in newly diagnosed gliomas. TERT exhibited improved prognosis when co-occurred with isocitrate dehydrogenase 1 (IDH1) and 1p19q alteration, but experienced inverse survival in the Mesenchymal subtype or tumor protein p53 (TP53) and epidermal growth factor receptor (EGFR) alteration. Furthermore, the five subtypes were classified based on the prognostic impact of the TERT mutation with different genetic backgrounds of glioma. CONCLUSION: We describe the TERT promoter mutation spectrum according to the histological, genetic, and molecular subtypes of glioma, which may aid in glioma subtype classification and have clinical implications.
Authors: Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape Journal: Cancer Cell Date: 2006-03 Impact factor: 31.743
Authors: Hiroko Ohgaki; Pierre Dessen; Benjamin Jourde; Sonja Horstmann; Tomofumi Nishikawa; Pier-Luigi Di Patre; Christoph Burkhard; Danielle Schüler; Nicole M Probst-Hensch; Paulo César Maiorka; Nathalie Baeza; Paola Pisani; Yasuhiro Yonekawa; M Gazi Yasargil; Urs M Lütolf; Paul Kleihues Journal: Cancer Res Date: 2004-10-01 Impact factor: 12.701
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: D Arango; A J Wilson; Q Shi; G A Corner; M J Arañes; C Nicholas; M Lesser; J M Mariadason; L H Augenlicht Journal: Br J Cancer Date: 2004-11-29 Impact factor: 7.640
Authors: Branka Powter; Sarah A Jeffreys; Heena Sareen; Adam Cooper; Daniel Brungs; Joseph Po; Tara Roberts; Eng-Siew Koh; Kieran F Scott; Mila Sajinovic; Joey Y Vessey; Paul de Souza; Therese M Becker Journal: J Cancer Res Clin Oncol Date: 2021-02-06 Impact factor: 4.553
Authors: Edaise M da Silva; Pier Selenica; Mahsa Vahdatinia; Fresia Pareja; Arnaud Da Cruz Paula; Lorenzo Ferrando; Andrea M Gazzo; Higinio Dopeso; Dara S Ross; Ariya Bakhteri; Nadeem Riaz; Sarat Chandarlapaty; Pedram Razavi; Larry Norton; Hannah Y Wen; Edi Brogi; Britta Weigelt; Hong Zhang; Jorge S Reis-Filho Journal: NPJ Breast Cancer Date: 2021-04-16
Authors: Silvia Giunco; Paolo Boscolo-Rizzo; Enrica Rampazzo; Giancarlo Tirelli; Lara Alessandrini; Roberto Di Carlo; Marco Rossi; Piero Nicolai; Anna Menegaldo; Valentina Carraro; Margherita Tofanelli; Luigia Bandolin; Giacomo Spinato; Enzo Emanuelli; Monica Mantovani; Marco Stellin; Rossana Bussani; Angelo Paolo Dei Tos; Maria Guido; Marzia Morello; Jonathan Fussey; Giovanni Esposito; Jerry Polesel; Anita De Rossi Journal: Front Oncol Date: 2021-11-10 Impact factor: 6.244
Authors: Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre Journal: Genes (Basel) Date: 2018-05-03 Impact factor: 4.096